Impact Capital Partners LLC Makes New Investment in Bruker Co. (NASDAQ:BRKR)

Impact Capital Partners LLC acquired a new position in shares of Bruker Co. (NASDAQ:BRKR) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,460 shares of the medical research company’s stock, valued at approximately $203,000.

Other hedge funds have also recently bought and sold shares of the company. FMR LLC boosted its stake in shares of Bruker by 21.4% in the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock valued at $987,981,000 after buying an additional 2,521,904 shares during the period. Vaughan Nelson Investment Management L.P. boosted its stake in shares of Bruker by 140.3% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company’s stock valued at $66,930,000 after buying an additional 666,617 shares during the period. Point72 DIFC Ltd boosted its stake in shares of Bruker by 4,875.9% in the third quarter. Point72 DIFC Ltd now owns 470,171 shares of the medical research company’s stock valued at $32,470,000 after buying an additional 460,722 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Bruker by 1,933.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 410,234 shares of the medical research company’s stock valued at $28,331,000 after buying an additional 390,057 shares during the period. Finally, State Street Corp boosted its stake in shares of Bruker by 9.6% in the third quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock valued at $250,501,000 after buying an additional 318,808 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Stock Performance

NASDAQ BRKR opened at $45.97 on Friday. The company has a market capitalization of $6.97 billion, a price-to-earnings ratio of 60.49, a PEG ratio of 2.16 and a beta of 1.18. Bruker Co. has a twelve month low of $44.11 and a twelve month high of $94.86. The stock has a fifty day simple moving average of $53.93 and a 200 day simple moving average of $58.57. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Sell-side analysts expect that Bruker Co. will post 2.69 EPS for the current year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Monday, March 17th will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a yield of 0.44%. Bruker’s payout ratio is currently 26.32%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BRKR. UBS Group initiated coverage on Bruker in a research note on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price target for the company. Barclays cut their target price on Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Guggenheim restated a “buy” rating on shares of Bruker in a research note on Monday, February 24th. The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price for the company in a research note on Thursday, December 5th. Finally, Bank of America upped their target price on Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Bruker has a consensus rating of “Moderate Buy” and a consensus price target of $70.50.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.